Pancreatic cancer clinical trial opens in Glasgow as part of game-changing effort to transform future for people affected
A clinical trial for people with advanced pancreatic cancer has opened at the Beatson West of Scotland Cancer Centre in Glasgow, as part of the major PRECISION Panc programme, which represents the largest ever single fund for pancreatic cancer research so far.
Pancreatic Cancer UK says it welcomes the launch of the PRIMUS-001 clinical trial and would like to encourage people with advanced pancreatic cancer to find out if they may be suitable for the trial. The trial will offer a vital treatment option for people with the disease, and as part of the wider PRECISION Panc programme it will also collect tissue samples from participants for molecular profiling, which could lead to vital new insights into the development of the disease in the future. It is hoped that around 658 people with advanced pancreatic cancer will be recruited onto the clinical trial.
Anna Jewell, our Director of Operations, said: “It’s incredibly exciting to see the first stages of this game-changing effort to change the future for people with pancreatic cancer. The clinical trial in Glasgow will provide a much-needed new treatment option for eligible patients with a disease which sadly has so few treatments available, and we would encourage patients to ask their doctor or consultant if they think this trial would be suitable for them.
“The overall aim of PRECISION Panc is to make precision medicine a reality for more people with pancreatic cancer through building up knowledge that will ultimately allow clinicians to match patients with the most suitable treatment or clinical trial for them. We are proud to be a part of this vitally important work for everyone affected by this tough disease.”
To find out more about the PRIMUS-001 clinical trial, visit www.precisionpanc.org
The PRECISION Panc programme was launched in Scotland in March, following on from a £10 million donation from Cancer Research UK and around £23 million from other organisations, and was heralded by Pancreatic Cancer UK as marking a step change in the treatment of the disease. The initiative ultimately aims to ensure the right patient gets the right treatment at the right time, by recruiting patients more quickly onto the clinical trials that are likely to be most effective for their particular tumour. The hope is that this approach will lead to hundreds of patients living longer with the disease, which just 4.6 per cent of patients in Scotland survive beyond five years. PRECISION Panc is being led by Professor Andrew Biankin at the University of Glasgow. Professor Biankin is also a member of Pancreatic Cancer UK’s Scientific Advisory Board.
In a separate Glasgow initiative, it was announced in September that the next generation of pancreatic cancer researchers would investigate how the disease grows and spreads and aim to discover new treatments, thanks to grants of £500,000 from Pancreatic Cancer UK, £75,000 from the Chief Scientist Office and £50,000 from Pancreatic Cancer Scotland.
Five PhD students have started four years of research as part of Pancreatic Cancer UK’s Future Leaders Academy, based at the Cancer Research UK Beatson Institute in Glasgow. It is hoped that the students will not only make vital breakthroughs in understanding and treating the disease, but will also remain committed to the disease throughout their careers, and help to solve another key challenge facing pancreatic cancer research.